Publications by authors named "James D Clark"

Claim this Profile
U
Understanding mental toughness at a Women's Australian rules football club.
James D Clark, Clifford J Mallett, Gene M Moyle, Tristan J Coulter

Psychol Sport Exerc· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Perceptions of Elite Professional Rugby League Players and Staff on the National Rugby League Annual Calendar: A Mixed-Methods Study.
Lewis A Fazackerley, Geoffrey M Minett, James D Clark, Vincent G Kelly

Sports Med Open· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Competitive Situations Requiring Mental Toughness in Women's Australian Rules Football.
James D Clark, Clifford J Mallett, Gene M Moyle, Tristan J Coulter

J Sports Sci· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Nan Bing, Huanyu Zhou, Xing Chen, Tomohiro Hirose, Yuta Kochi, James D Clark

Arthritis Rheumatol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
Brian S Gerstenberger, Catherine Ambler, Eric P Arnold, Mary-Ellen Banker, Matthew F Brown, James D Clark

J Med Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
Karen M Page, Mayte Suarez-Farinas, Maria Suprun, Weidong Zhang, Sandra Garcet, James D Clark

J Invest Dermatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences.
Brian S Gerstenberger, Mary Ellen Banker, James D Clark, Martin E Dowty, Andrew Fensome

Sci Rep· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
Andrew Fensome, Catherine M Ambler, Eric Arnold, Mary Ellen Banker, James D Clark

Bioorg Med Chem· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
Ronald van Vollenhoven, Eun Bong Lee, Sander Strengholt, Christopher Mojcik, Hernan Valdez, James D Clark

Arthritis Rheumatol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).
Andrew Fensome, Catherine M Ambler, Eric Arnold, Mary Ellen Banker, Matthew F Brown, James D Clark

J Med Chem· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Kent J Weinhold, Jack F Bukowski, Todd V Brennan, Robert J Noveck, Janet S Staats, James D Clark

Clin Immunol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.
Michael L Vazquez, Neelu Kaila, Joseph W Strohbach, John D Trzupek, Matthew F Brown, James D Clark

J Med Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Jean-Baptiste Telliez, Martin E Dowty, Lu Wang, Jason Jussif, Tsung Lin, James D Clark

ACS Chem Biol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network pharmacology of JAK inhibitors.
Devapregasan Moodley, Hideyuki Yoshida, Sara Mostafavi, Natasha Asinovski, Adriana Ortiz-Lopez, James D Clark

Proc Natl Acad Sci U S A· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Jennifer A Hodge, Thomas T Kawabata, Sriram Krishnaswami, James D Clark, Jean-Baptiste Telliez

Clin Exp Rheumatol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
James Krueger, James D Clark, Mayte Suárez-Fariñas, Judilyn Fuentes-Duculan, Inna Cueto

J Allergy Clin Immunol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parsing the Interferon Transcriptional Network and Its Disease Associations.
Sara Mostafavi, Hideyuki Yoshida, Devapregasan Moodley, Hugo LeBoité, Katherine Rothamel, James D Clark

Cell· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Milbemycin oxime (Interceptor) treatment of amphipod parasites (Hyperiidae) from several host jellyfish species.
Jennifer L Boonstra, Maureen E Koneval, James D Clark, Mark Schick, Malissa Smith

J Zoo Wildl Med· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
James D Clark, Mark E Flanagan, Jean-Baptiste Telliez

J Med Chem· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variants within STAT genes reveal association with anticitrullinated protein antibody-negative rheumatoid arthritis in 2 European populations.
Maria Seddighzadeh, Antonio Gonzalez, Bo Ding, Aida Ferreiro-Iglesias, Juan J Gomez-Reino, James D Clark

J Rheumatol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of an inhibitor of cytosolic phospholipase A2α for the treatment of asthma.
Christopher A Hewson, Sheena Patel, Luigino Calzetta, Hinnah Campwala, Suzanne Havard, Philip A Clarke, James D Clark, Nicholas P Clarke

J Pharmacol Exp Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The balance of expression of PTPN22 splice forms is significantly different in rheumatoid arthritis patients compared with controls.
Marcus Ronninger, Yongjing Guo, Klementy Shchetynsky, Andrew Hill, Mohsen Khademi, James D Clark

Genome Med· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytosolic phospholipase A2α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCs.
Paresh Thakker, Suzana Marusic, Nancy L Stedman, Katherine L Lee, John C McKew, James D Clark

J Immunol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of perzinfotel and a proprietary phospholipase A(2) inhibitor on kinetic gait and subjective lameness scores in dogs with sodium urate-induced synovitis.
Steven C Budsberg, Bryan T Torres, Raphael J Zwijnenberg, C Mark Eppler, James D Clark

Am J Vet Res· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cPLA2α inhibitor efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid.
Cheryl L Nickerson-Nutter, Debra Goodwin, Marina W H Shen, Christy Damphousse, Weili Duan, James D Clark

Neuropharmacology· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis